VBL Therapeutics receives FDA fast track designation for ofra-vec for the treatment of platinum-resistant ovarian cancer

VBL Therapeutics

26 April 2022 - OVAL Phase 3 top-line progression-free survival primary outcome data for ofra-vec expected in 2H 2022; with positive results, VBL anticipates submitting a biologics license application in 1H, 2023.

VBL Therapeutics today announced that the U.S. FDA has granted fast track designation for ofra-vec (ofranergene obadenovec or VB-111) in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer.

Read VBL Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder